Potential therapeutic strategies for Alzheimer's disease targeting or beyond β -Amyloid: Insights from clinical trials

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Jia, Qiutian ^a   Deng, Yulin ^a   Qing, Hong ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; 5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ADUCANUMAB; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ATORVASTATIN; AVAGACESTAT; BAPINEUZUMAB; BEGACESTAT; CRENEZUMAB; DAVUNETIDE; ETAZOLATE; GANTENERUMAB; HOMOTAURINE; IMMUNOGLOBULIN G; LITHIUM; METHAMPHETAMINE; NEUROTROPHIN; NICASTRIN; NICOTINAMIDE; PIOGLITAZONE; PONEZUMAB; PRESENILIN; ROSIGLITAZONE; SEMAGACESTAT; SIMVASTATIN; SOLANEZUMAB; VALPROIC ACID; BIOLOGICAL MARKER;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NEUROTRANSMISSION; NONHUMAN; PASSIVE IMMUNIZATION; PHARMACEUTICAL CARE; PROTEIN AGGREGATION; REVIEW; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROFIBRILLARY TANGLE; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEUROFIBRILLARY TANGLES;

EID: 84929051777     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/837157     Document Type: Review

References (215)

1. M. Goedert and M. G. Spillantini, "A century of Alzheimers disease, " Science, vol. 314, no. 5800, pp. 777-781, 2006.
2. G. E. Berrios, "Alzheimers disease: a conceptual history, " International Journal of Geriatric Psychiatry, vol. 5, no. 6, pp. 355-365, 1990.
3. M. Hashimoto, E. Rockenstein, L. Crews, and E. Masliah, "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimers and Parkinsons diseases, " NeuroMolecular Medicine, vol. 4, no. 1-2, pp. 21-36, 2003.
4. L. Bckman, S. Jones, A. Berger, E. J. Laukka, and B. J. Small, "Multiple cognitive deficits during the transition to Alzheimers disease, " Journal of Internal Medicine, vol. 256, no. 3, pp. 195-204, 2004.
5. E. Arnáiz and O. Almkvist, "Neuropsychological features of mild cognitive impairment and preclinical Alzheimers disease, " Acta Neurologica Scandinavica, vol. 107, no. 179, pp. 34-41, 2003.
6. H. Frstl and A. Kurz, "Clinical features of Alzheimers disease, " European Archives of Psychiatry and Clinical Neuroscience, vol. 249, no. 6, pp. 288-290, 1999.
7. P. D. Meek, E. K. McKeithan, and G. T. Schumock, "Economic considerations in Alzheimers disease, " Pharmacotherapy, vol. 18, no. 2, pp. 68-82, 1998.
8. A. Wimo, L. Jnsson, A. Gustavsson et al. , "The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project, " International Journal of Geriatric Psychiatry, vol. 26, no. 8, pp. 825-832, 2011.
9. C. A. Thompson, K. Spilsbury, J. Hall, Y. Birks, C. Barnes, and J. Adamson, "Systematic review of information and support interventions for caregivers of people with dementia, " BMC Geriatrics, vol. 7, article 18, 2007.
10. J. Schneider, J. Murray, S. Banerjee, and A. Mann, "EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimers disease: I-Factors associated with carer burden, " International Journal of Geriatric Psychiatry, vol. 14, pp. 651-661, 1999.
11. J. Murray, J. Schneider, S. Banerjee, and A. Mann, "EUROCARE, a cross-national study of co-resident spouse carers for people with Alzheimers disease: II-a qualitative analysis of the experience of caregiving, " International Journal of Geriatric Psychiatry, vol. 14, pp. 662-667, 1999.
12. C. P. Ferri, M. Prince, C. Brayne et al. , "Global prevalence of dementia: a Delphi consensus study, " The Lancet, vol. 366, no. 9503, pp. 2112-2117, 2005.
13. C. Reitz, C. Brayne, and R. Mayeux, "Epidemiology of Alzheimer disease, " Nature Reviews Neurology, vol. 7, no. 3, pp. 137-152, 2011.
14. M. Pohanka, "Cholinesterases, a target of pharmacology and toxicology, " Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 155, no. 3, pp. 219-230, 2011.
15. P. M. Doraiswamy and G. L. Xiong, "Pharmacological strategies for the prevention of Alzheimers disease, " Expert Opinion on Pharmacotherapy, vol. 7, no. 1, pp. 1-10, 2006.
16. A. Lle, S. M. Greenberg, and J. H. Growdon, "Current pharmacotherapy for Alzheimers disease, " Annual Review of Medicine, vol. 57, pp. 513-533, 2006.
17. C. W. Ritchie, D. Ames, T. Clayton, and R. Lai, "Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease, " The American Journal of Geriatric Psychiatry, vol. 12, no. 4, pp. 358-369, 2004.
18. A. Whitehead, C. Perdomo, R. D. Pratt, J. Birks, G. K. Wilcock, and J. G. Evans, "Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimers disease: a metaanalysis of individual patient data from randomised controlled trials, " International Journal of Geriatric Psychiatry, vol. 19, no. 7, pp. 624-633, 2004.
19. R. Bullock, "Efficacy and safety of memantine in moderateto-severe Alzheimer disease: the evidence to date, " Alzheimer Disease and Associated Disorders, vol. 20, no. 1, pp. 23-29, 2006.
20. M. L. Michaelis, "Drugs targeting Alzheimers disease: some things old and some things new, " Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 3, pp. 897-904, 2003.
21. R. Vassar, B. D. Bennett, S. Babu-Khan et al. , "β-Secretase cleavage of Alzheimers amyloid precursor protein by the transmembrane aspartic protease BACE, " Science, vol. 286, no. 5440, pp. 735-741, 1999.
22. R. Yan, M. J. Blenkowski, M. E. Shuck et al. , "Membraneanchored aspartyl proteasewithAlzheimers disease β-secretase activity, " Nature, vol. 402, no. 6761, pp. 533-537, 1999.
23. S. L. Roberds, J. Anderson, G. Basi et al. , "BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimers disease therapeutics, " Human Molecular Genetics, vol. 10, no. 12, pp. 1317-1324, 2001.
24. Y. Luo, B. Bolon, S. Kahn et al. , "Mice deficient in BACE1, the Alzheimers β-secretase, have normal phenotype and abolished β-amyloid generation, " Nature Neuroscience, vol. 4, no. 3, pp. 231-232, 2001.
25. M. Ohno, L. Chang, W. Tseng et al. , "Temporalmemory deficits in Alzheimers mouse models: rescue by genetic deletion of BACE1, " European Journal ofNeuroscience, vol. 23, no. 1, pp. 251-260, 2006.
26. M. Ohno, E. A. Sametsky, L. H. Younkin et al. , "BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimers disease, " Neuron, vol. 41, no. 1, pp. 27-33, 2004.
27. S. M. Harrison, A. J. Harper, J. Hawkins et al. , "BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes, " Molecular and Cellular Neuroscience, vol. 24, no. 3, pp. 646-655, 2003.
28. X. Hu, C. W. Hicks, W. He et al. , "Bace1 modulates myelination in the central and peripheral nervous system, " Nature Neuroscience, vol. 9, no. 12, pp. 1520-1525, 2006.
29. M. Willem, A. N. Garratt, B. Novak et al. , "Control of peripheral nerve myelination by the β-secretase BACE1, " Science, vol. 314, no. 5799, pp. 664-666, 2006.
30. D. Kobayashi, M. Zeller, T. Cole et al. , "BACE1 gene deletion: impact on behavioral function in a model of Alzheimers disease, " Neurobiology of Aging, vol. 29, no. 6, pp. 861-873, 2008.
31. X. Hu, W. He, C. Diaconu et al. , "Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves, "TheFASEB Journal, vol. 22, no. 8, pp. 2970-2980, 2008.
32. F. M. Laird, H. Cai, A. V. Savonenko et al. , "BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions, " Journal of Neuroscience, vol. 25, no. 50, pp. 11693-11709, 2005.
33. L. McConlogue, M. Buttini, J. P. Anderson et al. , "Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice, " Journal of Biological Chemistry, vol. 282, no. 36, pp. 26326-26334, 2007.
34. I. Hussain, "The potential for BACE1 inhibitors in the treatment of Alzheimers disease, " IDrugs, vol. 7, no. 7, pp. 653-658, 2004.
35. Y. Hamada and Y. Kiso, "Recent progress in the drug discovery of non-peptidic BACE1 inhibitors, " Expert Opinion on Drug Discovery, vol. 4, no. 4, pp. 390-416, 2009.
36. L. Michalik, J. Auwerx, J. P. Berger et al. , "International union of pharmacology. LXI. Peroxisome proliferator-activated receptors, " Pharmacological Reviews, vol. 58, no. 4, pp. 726-741, 2006.
37. S. Mandrekar-Colucci, J. Colleen Karlo, and G. E. Landreth, "Mechanisms underlying the rapid peroxisome proliferatoractivated receptor-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimers disease, " TheJournal ofNeuroscience, vol. 32, no. 30, pp. 10117-10128, 2012.
38. G. Landreth, Q. Jiang, S. Mandrekar, and M. Heneka, "PPAR agonists as therapeutics for the treatment of Alzheimers disease, " Neurotherapeutics, vol. 5, no. 3, pp. 481-489, 2008.
39. S. Craft, "The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged, " Archives of Neurology, vol. 66, no. 3, pp. 300-305, 2009.
40. Senate CoFUS, Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia, US Government Printing Office, Washington, DC, USA, 2010.
41. W. Chang, G. Koelsch, S. Wong et al. , "In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors, " Journal of Neurochemistry, vol. 89, no. 6, pp. 1409-1416, 2004.
42. A. K. Ghosh, N. Kumaragurubaran, L. Hong, G. Koelsh, and J. Tang, "Memapsin 2 (beta-secretase) inhibitors: drug development, " Current Alzheimer Research, vol. 5, no. 2, pp. 121-131, 2008.
43. J. J. N. Tang, "Beta-secretase as target for amyloid-reduction therapy, " Alzheimers & Dementia, vol. 5, no. 4, p. 74, 2009.
44. P. C. May, "Preclinical to clinical translation of APP biomarker responses to LY2886721, a potent, oral BACE1 inhibitor in phase II development for Alzheimers disease, " in Proceedings of the Neuroscience Meeting, Nanosymposium, Society for Neuroscience, vol. 542, p. 334.
45. M. Shoji, T. E. Golde, J. Ghiso et al. , "Production of the Alzheimer amyloid β protein by normal proteolytic processing, " Science, vol. 258, no. 5079, pp. 126-129, 1992.
46. C. Haass, M. G. Schlossmacher, A. Y. Hung et al. , "Amyloid beta-peptide is produced by cultured cells during normal metabolism, " Nature, vol. 359, no. 6393, pp. 322-325, 1992.
47. B. De Strooper, W. Annaert, P. Cupers et al. , "A presenilin-1-dependent -secretase-like protease mediates release of notch intracellular domain, " Nature, vol. 398, no. 6727, pp. 518-522, 1999.
48. D. B. Henley, P. C. May, R. A. Dean, and E. R. Siemers, "Development of semagacestat (LY450139), a functional -secretase inhibitor, for the treatment of Alzheimers disease, " Expert Opinion on Pharmacotherapy, vol. 10, no. 10, pp. 1657-1664, 2009.
49. B. P. Imbimbo, "Therapeutic potential of -secretase inhibitors and modulators, " Current Topics in Medicinal Chemistry, vol. 8, no. 1, pp. 54-61, 2008.
50. I. Maillard, S. H. Adler, and W. S. Pear, "Notch and the immune system, " Immunity, vol. 19, no. 6, pp. 781-791, 2003.
51. B. Z. Stanger, R. Datar, L. C. Murtaugh, and D. A. Melton, "Direct regulation of intestinal fate byNotch, " Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 102, no. 35, pp. 12443-12448, 2005.
52. X. Xia, S. Qian, S. Soriano et al. , "Loss of presenilin 1 is associated with enhanced β-catenin signaling and skin tumorigenesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10863-10868, 2001.
53. M. Nicolas, A. Wolfer, K. Raj et al. , "Notch1 functions as a tumor suppressor in mouse skin, " Nature Genetics, vol. 33, no. 3, pp. 416-421, 2003.
54. A. S. Fleisher, R. Raman, E. R. Siemers et al. , "Phase 2 safety trial targeting amyloid β productionwith a -secretase inhibitor in Alzheimer disease, " Archives of Neurology, vol. 65, no. 8, pp. 1031-1038, 2008.
55. R. J. Bateman, E. R. Siemers, K. G. Mawuenyega et al. , "A -secretase inhibitor decreases amyloid-β production in the central nervous system, " Annals of Neurology, vol. 66, no. 1, pp. 48-54, 2009.
56. R. S. Doody, R. Raman, M. Farlow et al. , "A phase 3 trial of semagacestat for treatment of Alzheimers disease, " The New England Journal of Medicine, vol. 369, no. 4, pp. 341-350, 2013.
57. T. Borgegård, S. Gustavsson, C. Nilsson et al. , "Alzheimers disease: presenilin 2-sparing -secretase inhibition is a tolerable Aβ peptide-lowering strategy, " The Journal of Neuroscience, vol. 32, no. 48, pp. 17297-17305, 2012.
58. B. Zhao, M. Yu, M. Neitzel et al. , "Identification of -secretase inhibitor potency determinants on presenilin, " The Journal of Biological Chemistry, vol. 283, no. 5, pp. 2927-2938, 2008.
59. L. Serneels, J. van Biervliet, K. Craessaerts et al. , "-Secretase heterogeneity in the aph1 subunit: relevance for alzheimers disease, " Science, vol. 324, no. 5927, pp. 639-642, 2009.
60. C. J. Crump, S. V. Castro, F. Wang et al. , "BMS-708, 163 targets presenilin and lacks notch-sparing activity, " Biochemistry, vol. 51, no. 37, pp. 7209-7211, 2012.
61. L. Ereshefsky, S. Jhee, M. Yen, S. Moran, S. Pretorius, and J. Adams, "Cerebrospinal fluid β-amyloid and dynabridging in Alzheimers disease drug development, " Biomarkers in Medicine, vol. 3, no. 6, pp. 711-721, 2009.
62. J. Wang, L. Ho, and G. M. Passinetti, "ThedevelopmentofNIC5-15. A natural anti-diabetic agent, in the treatment of Alzheimers disease, " Alzheimers & Dementia:The Journal of the Alzheimers Association, vol. 1, article 62, 2005.
63. H. Grossman, G. Marzloff, X. Luo, D. LeRoith, M. Sano, and G. Pasinetti, "NIC5-15 as a treatment for Alzheimers: safety, pharmacokinetics and clinical variables, " Alzheimers & Dementia, vol. 5, no. 4, supplement, p. P259, 2009.
64. S. Weggen, J. L. Eriksen, P. Das et al. , "A subset of NSAIDs lower amyloidogenicAβ42 independently of cyclooxygenase activity, " Nature, vol. 414, no. 6860, pp. 212-216, 2001.
65. T. Tomita, "Secretase inhibitors and modulators for Alzheimers disease treatment, " Expert Review of Neurotherapeutics, vol. 9, no. 5, pp. 661-679, 2009.
66. D. R. Galasko, N. Graff-Radford, S. May et al. , "Safety, tolerability, pharmacokinetics, and Aβ levels after short-term administration of R-flurbiprofen in healthy elderly individuals, " Alzheimer Disease and Associated Disorders, vol. 21, no. 4, pp. 292-299, 2007.
67. G. K. Wilcock, S. E. Black, S. B. Hendrix, K. H. Zavitz, E. A. Swabb, and M. A. Laughlin, "Efficacy and safety of tarenflurbil in mild to moderate Alzheimers disease: a randomised phase II trial, " The Lancet Neurology, vol. 7, no. 6, pp. 483-493, 2008.
68. R. C. Green, L. S. Schneider, D. A. Amato et al. , "Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial, " Journal of the American Medical Association, vol. 302, no. 23, pp. 2557-2564, 2009.
69. B. P. Imbimbo, "Why did tarenflurbil fail in alzheimers disease" Journal of AlzheimersDisease, vol. 17, no. 4, pp. 757-760, 2009.
70. S. Sivilia, L. Lorenzini, A. Giuliani et al. , "Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice, " BMC Neuroscience, vol. 14, article 44, 2013.
71. G. Poli, E. Corda, B. Lucchini et al. , "Therapeutic effect of CHF5074, a new -secretase modulator, in a mouse model of scrapie, " Prion, vol. 6, no. 1, pp. 62-72, 2012.
72. A. Hall, R. L. Elliott, G. M. P. Giblin et al. , "Piperidine-derived -secretase modulators, " Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 3, pp. 1306-1311, 2010.
73. R. J. van Marum, "Current and future therapy in Alzheimers disease, " Fundamental & Clinical Pharmacology, vol. 22, no. 3, pp. 265-274, 2008.
74. H. H. Griffiths, I. J. Morten, and N. M. Hooper, "Emerging and potential therapies for Alzheimers disease, " Expert Opinion on Therapeutic Targets, vol. 12, no. 6, pp. 693-704, 2008.
75. M. Marcade, J. Bourdin, N. Loiseau et al. , "Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing, " Journal of Neurochemistry, vol. 106, no. 1, pp. 392-404, 2008.
76. L. Desire, M. Marcade, H. Peillon, D. Drouin, and O. Sol, "Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase, " Alzheimers & Dementia, vol. 5, no. 4, pp. P255-P256, 2009.
77. R. Etcheberrigaray, M. Tan, I. Dewachtert et al. , "Therapeutic effects of PKC activators in Alzheimers disease transgenic mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 30, pp. 11141-11146, 2004.
78. D. L. Sparks, M. N. Sabbagh, D. J. Connor et al. , "Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results, " Archives of Neurology, vol. 62, no. 5, pp. 753-757, 2005.
79. R. W. Jones, M. Kivipelto, H. Feldman et al. , "The Atorvastatin/ Donepezil in Alzheimers Disease Study (LEADe): design and baseline characteristics, " Alzheimers and Dementia, vol. 4, no. 2, pp. 145-153, 2008.
80. H. H. Feldman, R. S. Doody, M. Kivipelto et al. , "Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe, " Neurology, vol. 74, no. 12, pp. 956-964, 2010.
81. R. G. Riekse, G. Li, E. C. Petrie et al. , "Effect of statins on Alzheimers disease biomarkers in cerebrospinal fluid, " Journal of Alzheimers Disease, vol. 10, no. 4, pp. 399-406, 2006.
82. M. Calamai, F. Chiti, and C. M. Dobson, "Amyloid fibril formation can proceed from different conformations of a partially unfolded protein, " Biophysical Journal, vol. 89, no. 6, pp. 4201-4210, 2005.
83. A. E. Roher, K. C. Palmer, E. C. Yurewicz, M. J. Ball, and B. D. Greenberg, "Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue, " Journal of Neurochemistry, vol. 61, no. 5, pp. 1916-1926, 1993.
84. P. S. Aisen, D. Saumier, R. Briand et al. , "A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease, " Neurology, vol. 67, no. 10, pp. 1757-1763, 2006.
85. H. Amijee and D. I. C. Scopes, "The quest for smallmolecules as amyloid inhibiting therapies for Alzheimers disease, " Journal of Alzheimers Disease, vol. 17, no. 1, pp. 33-47, 2009.
86. J. McLaurin, M. E. Kierstead, M. E. Brown et al. , "Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model, " Nature Medicine, vol. 12, no. 7, pp. 801-808, 2006.
87. S. Salloway, R. Sperling, S. Gilman et al. , "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease, " Neurology, vol. 73, no. 24, pp. 2061-2070, 2009.
88. Elan Elan and Transition Therapeutics announce modifications to ELND005 phase II clinical trials in Alzheimers disease 2009.
89. S. A. Mandel, T. Amit, L. Kalfon, L. Reznichenko, O. Weinreb, and M. B. H. Youdim, "Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: Special reference to epigallocatechin gallate (EGCG), " Journal of Alzheimers Disease, vol. 15, no. 2, pp. 211-222, 2008.
90. P. A. Adlard, R. A. Cherny, D. I. Finkelstein et al. , "Rapid restoration of cognition in Alzheimers transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta, " Neuron, vol. 59, no. 1, pp. 43-55, 2008.
91. D. Schenk, R. Barbour, W. Dunn et al. , "Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse, " Nature, vol. 400, no. 6740, pp. 173-177, 1999.
92. M. N. Pangalos, S. J. Jacobsen, and P. H. Reinhart, "Disease modifying strategies for the treatment of Alzheimers disease targeted at modulating levels of the β-amyloid peptide, " Biochemical Society Transactions, vol. 33, no. 4, pp. 553-558, 2005.
93. J.-M. Orgogozo, S. Gilman, J.-F. Dartigues et al. , "Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization, " Neurology, vol. 61, no. 1, pp. 46-54, 2003.
94. J. A. R. Nicolll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, "Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report, " Nature Medicine, vol. 9, no. 4, pp. 448-452, 2003.
95. I. Ferrer, M. B. Rovira, M. L. S. Guerra, M. J. Rey, and F. Costa-Jussá, "Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimers disease, " Brain Pathology, vol. 14, no. 1, pp. 11-20, 2004.
96. E. Masliah, L. Hansen, A. Adame et al. , "Aβ vaccination effects on plaque pathology in the absence of encephalitis inAlzheimer disease, " Neurology, vol. 64, no. 1, pp. 129-131, 2005.
97. B. Winblad, L. Minthon, and A. Floesser, "Results of the firstin-man study with the active Aβ immunotherapy CAD106 in Alzheimer patients, " Alzheimers & Dementia, vol. 5, no. 4, supplement, pp. P113-P114, 2009.
98. A. Schneeberger, M. Mandler, O. Otava, W. Zauner, F. Mattner, and W. Schmidt, "Development of AFFITOPE vaccines for Alzheimers Disease (AD)-from concept to clinical testing, " Journal of Nutrition, Health and Aging, vol. 13, no. 3, pp. 264-267, 2009.
99. F. Bard, C. Cannon, R. Barbour et al. , "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, " Nature Medicine, vol. 6, no. 8, pp. 916-919, 2000.
100. S. Oddo, L. Billings, J. P. Kesslak, D. H. Cribbs, and F. M. LaFerla, "Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome, " Neuron, vol. 43, no. 3, pp. 321-332, 2004.
101. D. M. Wilcock, N. Gharkholonarehe, W. E. Van Nostrand, J. Davis, M. P. Vitek, and C. A. Colton, "Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimers disease, " The Journal of Neuroscience, vol. 29, no. 25, pp. 7957-7965, 2009.
102. I. Klyubin, D. M. Walsh, C. A. Lemere et al. , "Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo, " Nature Medicine, vol. 11, no. 5, pp. 556-561, 2005.
103. E. R. Siemers, S. Friedrich, R. A. Dean et al. , "P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimers disease, " Alzheimers&Dementia, vol. 4, no. 4, supplement, p. T774, 2008.
104. J. E. McElhaney and R. B. Effros, "Immunosenescence: what does it mean to health outcomes in older adults" Current Opinion in Immunology, vol. 21, no. 4, pp. 418-424, 2009.
105. K. Iqbal and I. Grundke-Iqbal, "Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention, " Journal of Cellular andMolecularMedicine, vol. 12, no. 1, pp. 38-55, 2008.
106. M. A. Meraz-Rs, K. I. Lira-de Len, V. Campos-Pena, M. A. de Anda-Hernández, and R. Mena-Lpez, "Tau oligomers andaggregation in Alzheimers disease, " Journal of Neurochemistry, vol. 112, no. 6, pp. 1353-1367, 2010.
107. A. J. Myers, M. Kaleem, L. Marlowe et al. , "TheH1c haplotype at theMAPT locus is associated with Alzheimers disease, " Human Molecular Genetics, vol. 14, no. 16, pp. 2399-2404, 2005.
108. N. Brouwers, K. Sleegers, S. Engelborghs et al. , "Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimers disease, " Brain, vol. 129, no. 11, pp. 2984-2991, 2006.
109. J. J. Pei, M. Sjgren, and B. Winblad, "Neurofibrillary degeneration in Alzheimers disease: from molecular mechanisms to identification of drug targets, " Current Opinion in Psychiatry, vol. 21, no. 6, pp. 555-561, 2008.
110. L. Martin, X. Latypova, C. M. Wilsonet al. , "Tauproteinkinases: involvement in Alzheimers disease, " Ageing Research Reviews, vol. 12, no. 1, pp. 289-309, 2013.
111. J. Pei, T. Tanaka, Y. Tung, E. Braak, K. Iqbal, and I. Grundke-Iqbal, "Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain, " Journal of Neuropathology and Experimental Neurology, vol. 56, no. 1, pp. 70-78, 1997.
112. K. Leroy, Z. Yilmaz, and J. P. Brion, "Increased level of active GSK-3β in Alzheimers disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration, " Neuropathology and Applied Neurobiology, vol. 33, no. 1, pp. 43-55, 2007.
113. P. N. Tariot and P. S. Aisen, "Can lithiumor valproate untie tangles in Alzheimers disease"The Journal of Clinical Psychiatry, vol. 70, no. 6, pp. 919-921, 2009.
114. H. Hampel, M. Ewers, K. Brger et al. , "Lithium trial in Alzheimers disease: a randomized, single-blind, placebocontrolled, multicenter 10-week study, " The Journal of Clinical Psychiatry, vol. 70, no. 6, pp. 922-931, 2009.
115. L. Seren, M. Coma, M. Rodruez et al. , "A novel GSK-3β inhibitor reduces Alzheimers pathology and rescues neuronal loss in vivo, " Neurobiology of Disease, vol. 35, no. 3, pp. 359-367, 2009.
116. W. Noble, V. Olm, K. Takata et al. , "Cdk5 is a key factor in tau aggregation and tangle formation in vivo, " Neuron, vol. 38, no. 4, pp. 555-565, 2003.
117. Y. Wen, E. Planel, M. Herman et al. , "Interplay between cyclindependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing, " Journal of Neuroscience, vol. 28, no. 10, pp. 2624-2632, 2008.
118. C. M. Wischik, P. C. Edwards, R. Y. K. Lai, M. Roth, and C. R. Harrington, "Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 11213-11218, 1996.
119. S. Deiana, C. R. Harrington, C. M. Wischik, and G. Riedel, "Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine, " Psychopharmacology, vol. 202, no. 1-3, pp. 53-65, 2009.
120. C. Wischik, "Rember: issues in design of a phase 3 disease modifying clinical trial of tau aggregation inhibitor therapy in Alzheimers disease, " Alzheimers & Dementia:The Journal of the Alzheimers Association, vol. 5, no. 4, p. P74, 2009.
121. Y. Wen, W. Li, E. C. Poteet et al. , "Alternative mitochondrial electron transfer as a novel strategy for neuroprotection, " The Journal of Biological Chemistry, vol. 286, no. 18, pp. 16504-16515, 2011.
122. P. D. Riha, J. C. Rojas, and F. Gonzalez-Lima, "Beneficial network effects of methylene blue in an amnestic model, " NeuroImage, vol. 54, no. 4, pp. 2623-2634, 2011.
123. D. E. Hurtado, L. Molina-Porcel, M. Iba et al. , "Aβ accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model, " The American Journal of Pathology, vol. 177, no. 4, pp. 1977-1988, 2010.
124. B. Zhang, J. Carroll, J. Q. Trojanowski et al. , "The microtubulestabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and alzheimer-like pathology in an interventional study with aged tau transgenic mice, " Journal of Neuroscience, vol. 32, no. 11, pp. 3601-3611, 2012.
125. K. N. Green, J. S. Steffan, H. Martinez-Coria et al. , "Nicotinamide restores cognition in Alzheimers disease transgenic mice via amechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau, " The Journal of Neuroscience, vol. 28, no. 45, pp. 11500-11510, 2008.
126. P. H. St George-Hyslop, "Piecing together Alzheimers, " Scientific American, vol. 283, no. 6, pp. 76-83, 2000.
127. L. A. Craig, N. S. Hong, and R. J. McDonald, "Revisiting the cholinergic hypothesis in the development of Alzheimers disease, " Neuroscience and Biobehavioral Reviews, vol. 35, no. 6, pp. 1397-1409, 2011.
128. I. Bezprozvanny and M. P. Mattson, "Neuronal calcium mishandling and the pathogenesis of Alzheimers disease, " Trends in Neurosciences, vol. 31, no. 9, pp. 454-463, 2008.
129. A. C. Santucci, P. D. Kanof, and V. Haroutunian, "Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats, " Psychopharmacology, vol. 99, no. 1, pp. 70-74, 1989.
130. C. L. Hunter, H. A. Bimonte-Nelson, M. Nelson, C. B. Eckman, and A. Granholm, "Behavioral and neurobiological markers of Alzheimers disease in Ts65Dn mice: effects of estrogen, " Neurobiology of Aging, vol. 25, no. 7, pp. 873-884, 2004.
131. L. M. Veng, A.-C. Granholm, and G. M. Rose, "Age-related sex differences in spatial learning and basal forebrain cholinergic neurons in F344 rats, " Physiology & Behavior, vol. 80, no. 1, pp. 27-36, 2003.
132. W. D. Hirst, B. Abrahamsen, F. E. Blaney et al. , "Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling, "Molecular Pharmacology, vol. 64, no. 6, pp. 1295-1308, 2003.
133. A. Bessis, C. Béchade, D. Bernard, and A. Roumier, "Microglial control of neuronal death and synaptic properties, " Glia, vol. 55, no. 3, pp. 233-238, 2007.
134. J. Calder, N. Brunet, D. Ciutat, M. Hereu, and J. E. Esquerda, "Development of microglia in the chick embryo spinal cord: implications in the regulation of motoneuronal survival and death, " Journal ofNeuroscience Research, vol. 87, no. 11, pp. 2447-2466, 2009.
135. H. Wake, A. J. Moorhouse, S. Jinno, S. Kohsaka, and J. Nabekura, "Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals, " Journal of Neuroscience, vol. 29, no. 13, pp. 3974-3980, 2009.
136. T. Wyss-Coray, "Inflammation in Alzheimer disease: driving force, bystander or beneficial response" Nature Medicine, vol. 12, no. 9, pp. 1005-1015, 2006.
137. J. Luber-Narod and J. Rogers, "Immune system associated antigens expressed by cells of the human central nervous system, " Neuroscience Letters, vol. 94, no. 1-2, pp. 17-22, 1988.
138. J. Rogers, J. Luber-Narod, S. D. Styren, and W. H. Civin, "Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimers disease, " Neurobiology of Aging, vol. 9, pp. 339-349, 1988.
139. D. G. Walker and L. F. Lue, "Investigations with cultured human microglia on pathogenic mechanisms of Alzheimers disease and other neurodegenerative diseases, " Journal of Neuroscience Research, vol. 81, no. 3, pp. 412-425, 2005.
140. A. Majumdar, H. Chung, G. Dolios et al. , "Degradation of fibrillar forms of Alzheimers amyloid β-peptide by macrophages, " Neurobiology of Aging, vol. 29, no. 5, pp. 707-715, 2008.
141. K. I. Andreasson, A. Savonenko, S. Vidensky et al. , "Agedependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice, " Journal of Neuroscience, vol. 21, no. 20, pp. 8198-8209, 2001.
142. X. Liang, L. Wu, Q. Wang et al. , "Function of COX-2 and prostaglandins in neurological disease, " Journal of Molecular Neuroscience, vol. 33, no. 1, pp. 94-99, 2007.
143. P. S. Aisen, "The potential of anti-inflammatory drugs for the treatment of Alzheimers disease, " Lancet Neurology, vol. 1, no. 5, pp. 279-284, 2002.
144. I. R. A. Mackenzie, "Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation, " Neurobiology of Aging, vol. 22, no. 6, pp. 819-822, 2001.
145. M. Hll, K. Lieb, and B. L. Fiebich, "Pathways of inflammatory activation in Alzheimers disease: potential targets for disease modifying drugs, " CurrentMedicinal Chemistry, vol. 9, no. 1, pp. 83-88, 2002.
146. M. E. Harris-White, T. Chu, S. A. Miller et al. , "Estrogen (E2) and glucocorticoid (Gc) effects on microglia and Aβ clearance in vitro and in vivo, " Neurochemistry International, vol. 39, no. 5-6, pp. 435-448, 2001.
147. P. Goyarzu, D. H. Malin, F. C. Lau et al. , "Blueberry supplemented diet: effects on object recognition memory and nuclear factor-kappa B levels in aged rats, "Nutritional Neuroscience, vol. 7, no. 2, pp. 75-83, 2004.
148. D. F. Obregon, K. Rezai-Zadeh, Y. Bai et al. , "ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced α-secretase cleavage of amyloid precursor protein, " The Journal of Biological Chemistry, vol. 281, no. 24, pp. 16419-16427, 2006.
149. D. Laurin, K. H. Masaki, D. J. Foley, L. R. White, and L. J. Launer, "Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study, " American Journal of Epidemiology, vol. 159, no. 10, pp. 959-967, 2004.
150. P. H. Reddy and M. F. Beal, "Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimers disease, " Trends in Molecular Medicine, vol. 14, no. 2, pp. 45-53, 2008.
151. C. A. Hansson Petersen, N. Alikhani, H. Behbahani et al. , "The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 13145-13150, 2008.
152. R. E. Davis and M. Williams, "Mitochondrial function and dysfunction: an update, " The Journal of Pharmacology and Experimental Therapeutics, vol. 342, no. 3, pp. 598-607, 2012.
153. D. J. Triggle, "Nous sommes tous des bacteries: implications for medicine, pharmacology and public health, " Biochemical Pharmacology, vol. 84, no. 12, pp. 1543-1550, 2012.
154. R. H. Swerdlow and S. M. Khan, "A "mitochondrial cascade hypothesis" for sporadic Alzheimers disease, " MedicalHypotheses, vol. 63, no. 1, pp. 8-20, 2004.
155. R. S. Doody, S. I. Gavrilova, M. Sano et al. , "Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimers disease: a randomised, double-blind, placebo-controlled study, " The Lancet, vol. 372, no. 9634, pp. 207-215, 2008.
156. R. A. Sperling, C. R. Jack Jr. , and P. S. Aisen, "Testing the right target and right drug at the right stage, " Science Translational Medicine, vol. 3, no. 111, Article ID 111cm33, 2011.
157. P. Tariot, M. Sabbagh, S. Flitman, P. Reyes, L. Taber, and L. Seely, "A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimers disease already receiving donepezil, " Alzheimers & Dementia, vol. 5, no. 4, supplement, p. P251, 2009.
158. E. M. Reiman, K. Chen, G. E. Alexander et al. , "Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimers dementia, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 284-289, 2004.
159. P. A. Maher and D. R. Schubert, "Metabolic links between diabetes and Alzheimers disease, " Expert Review of Neurotherapeutics, vol. 9, no. 5, pp. 617-630, 2009.
160. S. C. Correia, R. X. Santos, G. Perry, X. Zhu, P. IMoreira, and M. A. Smith, "Insulin-resistant brain state: the culprit in sporadic Alzheimers disease" Ageing Research Reviews, vol. 10, no. 2, pp. 264-273, 2011.
161. I. Clark, C. Atwood, R. Bowen, G. Paz-Filho, and B. Vissel, "Tumor necrosis factor-induced cerebral insulin resistance in Alzheimers disease links numerous treatment rationales, " Pharmacological Reviews, vol. 64, no. 4, pp. 1004-1026, 2012.
162. J. Butchart and C. Holmes, "Systemic and central immunity in Alzheimers disease: therapeutic implications, " CNS Neuroscience and Therapeutics, vol. 18, no. 1, pp. 64-76, 2012.
163. W. Q. Qiu and M. F. Folstein, "Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimers disease: review and hypothesis, " Neurobiology of Aging, vol. 27, no. 2, pp. 190-198, 2006.
164. F. J. Gil-Bea, M. Solas, A. Solomon et al. , "Insulin levels are decreased in the cerebrospinal fluid of women with prodomal alzheimers disease, " Journal of Alzheimers Disease, vol. 22, no. 2, pp. 405-413, 2010.
165. P. Dandona, I. Mohamed, H. Ghanim et al. , "Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3β in peripheral blood mononuclear cells, " The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 6, pp. 1783-1788, 2011.
166. P. L. Mcclean, V. Parthsarathy, E. Faivre, and C. Holscher, "The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimers disease, " Journal of Neuroscience, vol. 31, no. 17, pp. 6587-6594, 2011.
167. K. N. Manolopoulos, L.-O. Klotz, P. Korsten, S. R. Bornstein, and A. Barthel, "Linking Alzheimers disease to insulin resistance: the FoxO response to oxidative stress, " Molecular Psychiatry, vol. 15, no. 11, pp. 1046-1052, 2010.
168. S. M. De La Monte, M. Tong, N. Lester-Coll, M. Plater Jr. , and J. R. Wands, "Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimers disease, " Journal of Alzheimers Disease, vol. 10, no. 1, pp. 89-109, 2006.
169. S. Craft, L. D. Baker, T. J. Montine et al. , "Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitiveimpairment: A pilot clinical trial, " Archives of Neurology, vol. 69, no. 1, pp. 29-38, 2012.
170. M. Chartier-Harlin, M. Parfitt, S. Legrain et al. , "Apolipoprotein E, 4 allele as a major risk factor for sporadic early and lateonset forms of Alzheimers disease: analysis of the 19q13. 2 chromosomal region, " Human Molecular Genetics, vol. 3, no. 4, pp. 569-574, 1994.
171. H. Houlden, R. Crook, H. Backhovens et al. , "ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimers disease families, " The American Journal of Medical Genetics, vol. 81, pp. 117-121, 1998.
172. E. H. Corder, A. M. Saunders, W. J. Strittmatter et al. , "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers disease in late onset families, " Science, vol. 261, no. 5123, pp. 921-923, 1993.
173. G. Bu, "Apolipoprotein e and its receptors in Alzheimers disease: pathways, pathogenesis and therapy, " Nature Reviews Neuroscience, vol. 10, no. 5, pp. 333-344, 2009.
174. G. W. Rebeck, J. S. Reiter, D. K. Strickland, and B. T. Hyman, "Apolipoprotein E in sporadic Alzheimers disease: allelic variation and receptor interactions, " Neuron, vol. 11, no. 4, pp. 575-580, 1993.
175. Y. Namba, M. Tomonaga, H. Kawasaki, E. Otomo, and K. Ikeda, "Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimers disease and kuru plaque amyloid in Creutzfeldt-Jakob disease, " Brain Research, vol. 541, no. 1, pp. 163-166, 1991.
176. E. Kok, S. Haikonen, T. Luoto et al. , "Apolipoprotein Edependent accumulation of alzheimer disease-related lesions begins in middle age, " Annals of Neurology, vol. 65, no. 6, pp. 650-657, 2009.
177. R. J. Caselli, A. C. Dueck, D. Osborne et al. , "Longitudinal modeling of age-related memory decline and the APOE 4 effect, "The New England Journal of Medicine, vol. 361, no. 3, pp. 255-263, 2009.
178. G. J. Izaks, R. T. Gansevoort, A. M. vanderKnaap, G. Navis, R. P. F. Dullaart, and J. P. J. Slaets, "The association ofAPOE genotype with cognitive function in persons aged 35 years or older, " PLoS ONE, vol. 6, no. 11, Article ID e27415, 2011.
179. M. N. Haan, L. Shemanski, W. J. Jagust, T. A. Manolio, and L. Kuller, "The role of APOE 4 inmodulating effects of other risk factors for cognitive decline in elderly persons, " Journal of the American Medical Association, vol. 282, no. 1, pp. 40-46, 1999.
180. R. Peila, B. L. Rodriguez, and L. J. Launer, "Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study, " Diabetes, vol. 51, no. 4, pp. 1256-1262, 2002.
181. T. Kanekiyo, J. Zhang, Q. Liu, C. Liu, L. Zhang, and G. Bu, "Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-β uptake, " Journal of Neuroscience, vol. 31, no. 5, pp. 1644-1651, 2011.
182. J. Kim, J. M. Castellano, H. Jiang et al. , "Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance, " Neuron, vol. 64, no. 5, pp. 632-644, 2009.
183. J. M. Castellano, J. Kim, F. R. Stewart et al. , "Human apoE isoforms differentially regulate brain amyloid-β peptide clearance, " Science Translational Medicine, vol. 3, no. 89, Article ID 89ra57, 2011.
184. A. Rapp, B. Gmeiner, and M. Httinger, "Implication of apoE isoforms in cholesterolmetabolism by primary rat hippocampal neurons and astrocytes, " Biochimie, vol. 88, no. 5, pp. 473-483, 2006.
185. T. Vanmierlo, K. Rutten, J. Dederen et al. , "Liver X receptor activation restores memory in aged AD mice without reducing amyloid, " Neurobiology of Aging, vol. 32, no. 7, pp. 1262-1272, 2011.
186. P. E. Cramer, J. R. Cirrito, D. W. Wesson et al. , "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models, " Science, vol. 335, no. 6075, pp. 1503-1506, 2012.
187. N. F. Fitz, A. A. Cronican, M. Saleem et al. , "Abca1 deficiency affects Alzheimers disease-like phenotype in humanApoE4 but not in ApoE3-targeted replacement mice, " Journal of Neuroscience, vol. 32, no. 38, pp. 13125-13136, 2012.
188. D. R. Riddell, H. Zhou, T. A. Comery et al. , "The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimers disease, " Molecular and Cellular Neuroscience, vol. 34, no. 4, pp. 621-628, 2007.
189. H. Chen, Z. Liu, A. Meyer-Franke et al. , "Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons, " The Journal of Biological Chemistry, vol. 287, no. 8, pp. 5253-5266, 2012.
190. M. Aono, E. R. Bennett, K. S. Kim et al. , "Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures, " Neuroscience, vol. 116, no. 2, pp. 437-445, 2003.
191. P. E. Batchelor, D. M. Armstrong, S. N. Blaker, and F. H. Gage, "Nerve growth factor receptor and choline acetyltransferase colocalization in neurons within the rat forebrain: response to fimbria-fornix transection, " The Journal of Comparative Neurology, vol. 284, no. 2, pp. 187-204, 1989.
192. M. V. Sofroniew, C. L. Howe, and W. C. Mobley, "Nerve growth factor signaling, neuroprotection, and neural repair, " Annual Review of Neuroscience, vol. 24, pp. 1217-1281, 2001.
193. A. Granholm, D. Albeck, C. Bckman et al. , "A non-invasive system for delivering neural growth factors across the bloodbrain barrier: a review, " Reviews in the Neurosciences, vol. 9, no. 1, pp. 31-55, 1998.
194. T. Nonomura, C. Nishio, R. M. Lindsay, and H. Hatanaka, "Cultured basal forebrain cholinergic neurons from postnatal rats show both overlapping and non-overlapping responses to the neurotrophins, " Brain Research, vol. 683, no. 1, pp. 129-139, 1995.
195. P. M. Friden, L. R. Walus, P. Watson et al. , "Blood-brain barrier penetration and in vivo activity of an NGF conjugate, " Science, vol. 259, no. 5093, pp. 373-377, 1993.
196. F. H. Gage, M. B. Rosenberg, M. H. Tuszynski et al. , "Gene therapy in the CNS: intracerebral grafting of genetically modified cells, " Progress in Brain Research, vol. 86, pp. 205-217, 1990.
197. F. Hefti, "Development of effective therapy for Alzheimers disease based on neurotrophic factors, " Neurobiology of Aging, vol. 15, supplement 2, pp. S193-S194, 1994.
198. J. A. Hardy and G. A. Higgins, "Alzheimers disease: the amyloid cascade hypothesis, " Science, vol. 256, no. 5054, pp. 184-185, 1992.
199. P. Edison, H. A. Archer, R. Hinz et al. , "Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study, " Neurology, vol. 68, no. 7, pp. 501-508, 2007.
200. Y. Li, J. O. Rinne, L. Mosconi et al. , "Regional analysis of FDG and PIB-PET images in normal aging, mild cognitiveimpairment, and Alzheimers disease, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2169-2181, 2008.
201. W. L. Klein, "Aβ toxicity in Alzheimers disease: globular oligomers (ADDLs) as new vaccine and drug targets, " Neurochemistry International, vol. 41, no. 5, pp. 345-352, 2002.
202. D. J. Selkoe, "Alzheimers disease is a synaptic failure, " Science, vol. 298, no. 5594, pp. 789-791, 2002.
203. J. Hardy and D. J. Selkoe, "The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics, " Science, vol. 297, no. 5580, pp. 353-356, 2002.
204. R. M. Koffie, M. Meyer-Luehmann, T. Hashimoto et al. , "Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 4012-4017, 2009.
205. T. Oide, T. Kinoshita, and K. Arima, "Regression stage senile plaques in the natural course of Alzheimers disease, " Neuropathology and Applied Neurobiology, vol. 32, no. 5, pp. 539-556, 2006.
206. G. R. Zimmermann, J. Lehár, and C. T. Keith, "Multi-target therapeutics: when the whole is greater than the sum of the parts, " Drug Discovery Today, vol. 12, no. 1-2, pp. 34-42, 2007.
207. M. J. Millan, "Multi-target strategies for the improvedtreatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application, " Pharmacology andTherapeutics, vol. 110, no. 2, pp. 135-370, 2006.
208. R. L. Martone, H. Zhou, K. Atchison et al. , "Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein -secretase for the treatment of Alzheimers disease, " The Journal of Pharmacology and ExperimentalTherapeutics, vol. 331, no. 2, pp. 598-608, 2009.
209. B. Vellas, O. Sol, P. J. Snyder et al. , "EHT0202 in Alzheimers disease: a 3-Month, randomized, placebo-controlled, doubleblind study, " Current Alzheimer Research, vol. 8, no. 2, pp. 203-212, 2011.
210. S. Salloway, R. Sperling, R. Keren et al. , "A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease, " Neurology, vol. 77, no. 13, pp. 1253-1262, 2011.
211. C. Caltagirone, L. Ferrannini, N. Marchionni, G. Nappi, G. Scapagnini, and M. Trabucchi, "The potential protective effect of tramiprosate (homotaurine) against Alzheimers disease: a review, " Aging Clinical and Experimental Research, vol. 24, no. 6, pp. 580-587, 2012.
212. N. G. Faux, C. W. Ritchie, A. Gunn et al. , "PBT2 rapidly improves cognition in alzheimers disease: additional phase II analyses, " Journal of Alzheimers Disease, vol. 20, no. 2, pp. 509-516, 2010.
213. B. Winblad, N. Andreasen, L. Minthonet al. , "Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimers disease: randomised, double-blind, placebo-controlled, first-in-human study, " The Lancet Neurology, vol. 11, no. 7, pp. 597-604, 2012.
214. T. Del Ser, K. C. Steinwachs, H. J. Gertz et al. , "Treatment of Alzheimers disease with the GSK-3 inhibitor tideglusib: a pilot study, " Journal of Alzheimers Disease, vol. 33, no. 1, pp. 205-215, 2013.
215. G. Yang, Y. Wang, J. Tian, and J. P. Liu, "Huperzine a for Alzheimers disease: a systematic review and meta-analysis of randomized clinical trials, " PloS ONE, vol. 8, Article IDe74916, 2013.